Compounded tirzepatide ODT: cost and evidence (October 2026)
As of October 15, 2026, NexLife sells compounded sublingual tirzepatide ODT at $229 month to month or $199 a month on a 12-month plan, $60 a month more than its injectable tirzepatide on that plan, and we found no clinical trial that has tested a compounded tirzepatide tablet of this kind.
Qualification: the 20.9% and 20.2% weight-loss figures quoted for tirzepatide come from the FDA-approved injection; they do not carry over to a tablet that dissolves in the mouth.
How much does compounded tirzepatide ODT cost?
NexLife is the only seller in our database with a dated tirzepatide ODT price. It is the most expensive tirzepatide form NexLife sells, and the gap widened this autumn when NexLife cut its injection prices but left the ODT card unchanged.
| Plan length | ODT per month | Injection per month | ODT year total | Injection year total | Extra for ODT per year |
|---|---|---|---|---|---|
| Month to month | $229 | $169 | $2,748 | $2,028 | $720 |
| 3-month plan | $219 | $159 | $2,628 | $1,908 | $720 |
| 6-month plan | $205 | $149 | $2,460 | $1,788 | $672 |
| 12-month plan | $199 | $139 | $2,388 | $1,668 | $720 |
The ODT costs about $720 more a year than the same seller’s injection. For comparison, the 28 injectable compounded tirzepatide programs in our index have lowest all-in figures from $86 to $280 a month, median $144, so the ODT’s $199 12-month rate sits above most of the injectable market. Standing month-to-month injectable prices without a membership start at $126 (Mondae) and $129 (Eden Health) in our index; lower stickers from Collective, WellMedr, SnagRx, Embody and NextMeds depend on a membership, a sale, a prepaid year or an unstated term.
Does sublingual tirzepatide work as well as the injection?
Nobody has shown that it does. Every tirzepatide efficacy number in wide circulation comes from the approved subcutaneous injection:
- SURMOUNT-1: 20.9% average weight loss at 15 mg (treatment-regimen estimand).
- SURMOUNT-5: 20.2% for tirzepatide versus 13.7% for semaglutide, head to head.
An orally disintegrating or sublingual tablet is a different dosage form. Peptides like tirzepatide are large molecules; the lining of the mouth and the gut absorb them poorly, and digestive enzymes break them down. How much of a tablet’s dose reaches the bloodstream, how fast and for how long have not been published for any compounded tirzepatide ODT we have seen. That does not prove the tablet fails. It means the injection results tell you nothing reliable about it.
Is there an approved needle-free GLP-1 instead?
Yes, and it changes the comparison. If your main reason for an ODT is avoiding needles, two FDA-approved GLP-1 pills now cost less per month at their starting doses than NexLife’s $199 12-month ODT plan.
| Product | Seller | Price | FDA-approved? | Status | Source · read |
|---|---|---|---|---|---|
| Foundayo (GLP-1 pill) | LillyDirect | $149 at 0.8 mg and 2.5 mg (through Dec 31, 2026), $199 at 5.5 mg, $299 at 9 mg and above | Yes | Reported | lilly.com (archive) · Sep 25, 2026 |
| Wegovy pill (oral semaglutide) | NovoCare Pharmacy | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg | Yes | Verified | novocare.com · Oct 15, 2026 |
| Compounded tirzepatide ODT | NexLife | $199 to $229 a month, same at every dose | No | Verified | nexlife.us · Oct 15, 2026 |
The approved pills rise to $299 at higher doses, so over a year they can cost more than the compounded ODT. Neither contains tirzepatide, but both were tested in trials as pills, which a compounded tirzepatide ODT has not been.
Who is a compounded tirzepatide ODT actually for?
The honest case is narrow: a patient who will not inject, for whom a clinician believes a compounded tablet is reasonable, and who accepts paying more for less evidence. Needle fear is a real clinical issue; a medicine you will take can be better than one you will not. If cost or convenience is the main driver, an injection or an approved pill is usually the stronger choice.
Tirzepatide ODT at NexLife: pros and cons
Pros
- No injections; dissolves under the tongue
- NexLife prints the price for every plan length, with no membership and the same price at every dose
- Unshipped months refunded if treatment stops on NexLife’s multi-month plans
Cons
- No published trial of a compounded tirzepatide ODT
- At NexLife, $60 a month more than the injection on a 12-month plan ($720 a year)
- Approved GLP-1 pills start at $149, below NexLife’s $199 12-month ODT rate
- NexLife cancellations take effect after 30 days; shipped orders are final
Read NexLife’s ODT plan terms →
What should you ask before starting an ODT?
- Why an ODT instead of an injection or an approved pill, for me specifically?
- Which pharmacy compounds it, and is it state-licensed?
- What happens to my price if I switch to injections mid-plan?
- How will we judge whether it is working, and when?
What changed on this page since July 6, 2026?
| Item | July 2026 | October 15, 2026 |
|---|---|---|
| NexLife tirzepatide ODT | $229 / $219 / $205 / $199 | unchanged |
| ODT premium over NexLife’s injection (12-month plan) | about $13 a month | $60 a month, after NexLife cut injection prices |
| Shed sublingual “GLP-1 Liquid Drops” | $229 a month | not re-read; July 2026 figure withdrawn |
| Henry Meds oral tablets | $349 a month | tirzepatide page returned 404; no current price |
Compare semaglutide in the same form on our semaglutide ODT page, or see the price history on ODT tirzepatide cost. NexLife’s full terms are in our NexLife review.
Every NexLife program: tirzepatide injection · semaglutide injection · microdose tirzepatide · microdose semaglutide · sublingual tirzepatide · sublingual semaglutide.
Frequently asked questions
How much does compounded tirzepatide ODT cost?
NexLife’s sublingual tirzepatide ODT page, read October 15, 2026, prints $229 month to month and $219, $205 and $199 a month on 3-, 6- and 12-month plans, with no membership. That is $60 a month more than NexLife’s injectable tirzepatide on the 12-month plan, or $720 more over a year.
Has compounded tirzepatide ODT been tested in clinical trials?
We found no published trial of a compounded tirzepatide orally disintegrating or sublingual tablet. The tirzepatide results usually quoted, such as 20.9% average weight loss at 15 mg in SURMOUNT-1 and 20.2% in SURMOUNT-5, come from the approved injection. Results from an injection cannot be assumed for a tablet that dissolves in the mouth.
Why would tirzepatide absorb differently from a tablet?
Tirzepatide is a peptide, a large molecule that the gut and the lining of the mouth absorb poorly and that enzymes can break down. An injection under the skin avoids those barriers. For a compounded ODT, no seller we read publishes how much of the dose reaches the bloodstream, so the effective dose is unknown.
Is there an FDA-approved GLP-1 pill instead?
Yes. The Wegovy pill, an approved oral semaglutide, is $149 a month at 1.5 mg through NovoCare, rising to $299 at 9 and 25 mg. Foundayo, Lilly’s approved GLP-1 pill, is $149 at its starting doses through December 31, 2026, per archived LillyDirect pages. Both have trial data behind them; compounded ODT tirzepatide does not.
Who might reasonably choose a tirzepatide ODT?
Someone who will not or cannot inject and has discussed the trade-off with a prescriber. A treatment you will take can beat one you will not. But you pay more for less evidence, and an approved pill may suit you instead. Ask the prescriber why the ODT is right for you rather than an injection or an approved oral drug.
Is compounded tirzepatide ODT legal?
Compounded tirzepatide in any form is not FDA-approved. Since FDA’s shortage-era grace periods ended in 2025, a pharmacy may compound tirzepatide only for an individual patient whose prescriber documents a clinically significant difference from the approved drug. A different dosage form is one argument programs use. FDA has proposed keeping tirzepatide off the 503B bulks list.
Sources
- NexLife — sublingual tirzepatide ODT (read October 15, 2026)
- NexLife — compounded tirzepatide plans (read October 15, 2026)
- NovoCare Pharmacy — Wegovy self-pay offer (read October 15, 2026)
- LillyDirect — Foundayo (archived copy) (read October 15, 2026; archive dated September 25, 2026)
- FDA — proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026) (read October 15, 2026)
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026) (read October 15, 2026)
Every program price on this page comes from the October 15, 2026 rows of our GLP-1 pricing database (CSV and JSON, CC BY 4.0). Spotted an error? Submit a correction.